Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01)

The summary for the Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01): The National Institute of Mental Health invites research grant applications to develop innovative programs to advance therapeutics for NeuroAIDS. This Funding Opportunity Announcement (FOA) will support research programs that will advance central nervous system (CNS)-focused therapeutic approaches to: a) address HIV-associated neurocognitive disorders in HIV-infected individuals on highly active anti-retroviral therapy (HAART), b) eradicate persistent HIV-1 from the CNS during chronic infection, c) prevent establishment of HIV-1 in the brain during early infection, and d) assess the potential for CNS toxicity using HAART or candidate drugs that are currently in clinical studies to eradicate HIV-1. Studies to create or adapt existing animal models of HIV-1 infection in the CNS may be proposed to enable assessment of novel HIV CNS-focused therapeutic candidates. Multi-disciplinary, multi-project programs that are focused on improving neurocognition in HIV-infected persons are encouraged. A well defined, synergistic and milestone-driven plan for discovery, preclinical, and/or early clinical hypothesis-driven research should be presented. Public-private partnerships are encouraged but not required.

Federal Grant Title:	Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-13-267
Type of Funding:	Grant
CFDA Numbers:	93.242
CFDA Descriptions:	Mental Health Research Grants
Current Application Deadline:	Jan 07, 2016
Original Application Deadline:	Jan 07, 2016
Posted Date:	Jul 08, 2013
Creation Date:	Jul 08, 2013
Archive Date:	Feb 07, 2016
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH...; • Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional...; • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...; • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...